Displaying drugs 1751 - 1775 of 2778 in total
| Name | Weight | Structure | Description | Categories |
|---|---|---|---|---|
| Hydrocortisone butyrate | 432.557 C25H36O6 |  | A corticosteroid used to treat inflammatory and pruritic corticosteroid-responsive dermatoses. | Corticosteroids, Moderately Potent (Group II) |
| Bimatoprost | 415.5656 C25H37NO4 |  | A prostaglandin analog used to treat hypotrichosis of the eyelashes and intraocular pressure in open angle glaucoma or ocular hypertension. | Amides / Antihypertensive Agents / Prostaglandins, Synthetic |
| Salmeterol | 415.5656 C25H37NO4 |  | A long-acting beta-2 adrenergic receptor agonist used to treat asthma and COPD. | Agents producing tachycardia / Agents that produce hypertension |
| Simvastatin | 418.5662 C25H38O5 |  | An HMG-CoA reductase inhibitor used to lower lipid levels and reduce the risk of cardiovascular events including myocardial infarction and stroke. | Anticholesteremic Agents / Drugs causing inadvertant photosensitivity / Hydroxymethylglutaryl-CoA Reductase Inhibitors / Hypolipidemic Agents / Hypolipidemic Agents Indicated for Hyperlipidemia |
| Viomycin | 685.69 C25H43N13O10 |  | Viomycin is an essential component in the drug cocktail currently used to fight infections of Mycobacterium tuberculosis. | Anti-Bacterial Agents / Antibiotics, Antitubercular / Peptides, Cyclic / Protein Synthesis Inhibitors |
| Acarbose | 645.608 C25H43NO18 |  | An alpha-glucosidase inhibitor used in adjunctly with diet and exercise for the management of glycemic control in patients with type 2 diabetes mellitus. | Glycoside Hydrolase Inhibitors / Trisaccharides |
| Cetalkonium | 360.649 C25H46N |  | An antiseptic used as a preservative or to treat certain topical infections. | Anti-Infective Agents, Local / Surface-Active Agents |
| Carboprost tromethamine | 489.65 C25H47NO8 |  | A prostaglandin used to treat postpartum uterine hemorrhage due to atony when other methods of management have not been effective. | Prostaglandins |
| Plazomicin | 592.691 C25H48N6O10 |  | An aminoglycoside antibiotic used to treat complicated urinary tract infections. | Agents that produce neuromuscular block (indirect) / Aminoglycoside Antibacterials / Anti-Bacterial Agents / Antibacterials for Systemic Use / Antiinfectives for Systemic Use / Carbohydrates / Drugs that are Mainly Renally Excreted / Drugs that are Mainly Renally Excreted with a Narrow Therapeutic Index / Gentamicins / Glycosides / MATE 1 Inhibitors / MATE 2 Inhibitors / MATE inhibitors / Narrow Therapeutic Index Drugs / Nephrotoxic agents |
| Deferoxamine | 560.684 C25H48N6O8 |  | A chelating agent used to treat iron or aluminum toxicity and some blood transfusion dependent anemias. | Hydroxamic Acids / Iron Chelating Agents / Siderophores |
| Danicopan | 580.418 C26H23BrFN7O3 |  | A small molecule complement factor D inhibitor used to treat extravascular hemolysis in patients with paroxysmal nocturnal hemoglobinuria. | Amines / Amino Acids / Amino Acids, Cyclic / Amino Acids, Peptides, and Proteins / BCRP/ABCG2 Inhibitors / Complement Inactivating Agents / Heterocyclic Compounds, Fused-Ring / Imino Acids / P-glycoprotein inhibitors / Pyrazoles / Pyridines |
| Trametinib | 615.3948 C26H23FIN5O4 |  | A kinase inhibitor used alone or in combination with dabrafenib to treat patients with cancers with specific BRAF mutations, such as melanoma and non-small cell lung cancer. | Mitogen-activated protein kinase (MEK) inhibitors / Protein Kinase Inhibitors |
| Acalabrutinib | 465.517 C26H23N7O2 |  | A Bruton tyrosine kinase inhibitor used to treat mantle cell lymphoma, chronic lymphocytic leukemia, and small lymphocytic lymphoma. | Bruton's tyrosine kinase (BTK) inhibitors / Protein Kinase Inhibitors |
| Belumosudil | 452.518 C26H24N6O2 |  | An oral inhibitor of rho-associated coiled-coil-containing protein kinases (ROCK) used in the treatment of chronic graft-versus-host disease (GVHD). | Selective Immunosuppressants |
| Tucatinib | 480.532 C26H24N8O2 |  | A kinase inhibitor used to treat certain types of unresectable/metastatic HER-2 positive breast cancer. | Human epidermal growth factor receptor 2 (HER2) tyrosine kinase inhibitors |
| Tolvaptan | 448.941 C26H25ClN2O3 |  | A selective vasopressin V2-receptor antagonist to slow kidney function decline in patients at risk for rapidly progressing autosomal dominant polycystic kidney disease (ADPKD). Also used to treat hypervolemic and euvolemic hyponatremia. | Antidiuretic Hormone Receptor Antagonists / Benzazepines / Vasopressin V2 Receptor Antagonist |
| Alatrofloxacin | 558.518 C26H25F3N6O5 |  | A fluoroquinolone antibiotic used to treat a variety of bacterial infections. | Anti-Infective Agents / Topoisomerase II Inhibitors |
| Rupatadine | 415.97 C26H26ClN3 |  | A selective histamine H1 receptor antagonist and platelet activating factor (PAF) antagonist used to treat allergic rhinitis. | Platelet Activating Factor, antagonists & inhibitors |
| Flunarizine | 404.4948 C26H26F2N2 |  | A selective calcium-entry blocker used as migraine prophylaxis in patients with severe and frequent episodes who have not responded adequately to more common treatments. | Antivertigo Preparations |
| Sonidegib | 485.507 C26H26F3N3O3 |  | An antineoplastic agent used for the treatment of locally advanced recurrent basal cell carcinoma (BCC) following surgery and radiation therapy, or in cases where surgery or radiation therapy are not appropriate. | Hedgehog pathway inhibitors |
| Etrasimod | 457.493 C26H26F3NO3 |  | An S1P receptors modulator used to treat moderate to severely active ulcerative colitis in adults | Acids, Acyclic / Cytochrome P-450 CYP2C19 Substrates / Cytochrome P-450 CYP2C8 Substrates / Cytochrome P-450 CYP2C9 Substrates / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Substrates / Fatty Acids / Fatty Acids, Volatile / Heterocyclic Compounds, Fused-Ring / Lipids |
| Carindacillin | 494.56 C26H26N2O6S |  | A penicillin antibiotic used to treat a variety of infections, but is no longer marketed in the USA. | Penicillins With Extended Spectrum |
| Ceftobiprole medocaril | 690.66 C26H26N8O11S2 |  | A broad spectrum 5th-generation cephalosporin antibacterial indicated for certain kinds of pneumonia, bacteremia, and skin and skin structure infections, including those caused by MRSA. | Anti-Bacterial Agents |
| Tezacaftor | 520.505 C26H27F3N2O6 |  | A medication used to treat homozygous or heterozygous F508del mutation cystic fibrosis. | BCRP/ABCG2 Inhibitors / BCRP/ABCG2 Substrates / Cytochrome P-450 CYP1A2 Inhibitors / Cytochrome P-450 CYP1A2 Inhibitors (strength unknown) / Cytochrome P-450 CYP2B6 Inhibitors / Cytochrome P-450 CYP2B6 Inhibitors (strength unknown) / Cytochrome P-450 CYP2C19 Inhibitors / Cytochrome P-450 CYP2C19 inhibitors (strength unknown) / Cytochrome P-450 CYP2C8 Inhibitors / Cytochrome P-450 CYP2C8 Inhibitors (strength unknown) / Cytochrome P-450 CYP2D6 Inhibitors / Cytochrome P-450 CYP2D6 Inhibitors (strength unknown) / Cytochrome P-450 CYP3A Inducers / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inducers / Cytochrome P-450 CYP3A4 Inducers (strength unknown) / Cytochrome P-450 CYP3A4 Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors (strength unknown) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A5 Inducers / Cytochrome P-450 CYP3A5 Inducers (strength unknown) / Cytochrome P-450 CYP3A5 Substrates / Cytochrome P-450 Enzyme Inducers / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Dioxoles / Heterocyclic Compounds, Fused-Ring / OAT1/SLC22A6 inhibitors / OAT3/SLC22A8 Inhibitors / OATP1B1/SLCO1B1 Inhibitors / OATP1B1/SLCO1B1 Substrates / OATP1B3 inhibitors / OCT2 Inhibitors / P-glycoprotein inhibitors / P-glycoprotein substrates |
| Avapritinib | 498.57 C26H27FN10 |  | A selective tyrosine kinase inhibitor being investigated for the treatment of multidrug resistant gastrointestinal tumors. | Kinase Inhibitor |
Displaying drugs 1751 - 1775 of 2778 in total